

Product Name	:	IMU-935
Cat. No.	:	PC-20040
CAS No.	:	2299252-72-3
Molecular Formula	:	C ₂₂ H ₁₈ ClF ₄ N ₅ O ₂
Molecular Weight	:	495.86
Target	:	ROR
Solubility	:	10 mM in DMSO



Biological Activity

IMU-935 (Izumerogant, IMU935, IM105935) is a potent, selective and orally available inverse agonist / inhibitor of retinoic acid-related orphan receptor gamma (**ROR γ t**) with IC₅₀ of 24 nM.

IMU-935 is shown to be a DHODH Inhibitor with an IC₅₀ of 240 nM.

IMU-935 demonstrates synergistic inhibition of the secretion of IL-17A, IL-17F and IFNy with IC₅₀ concentrations of 3-5 nM tested in stimulated human lymphocytes.

IMU-935 inhibits Th17 differentiation of murine cells (IC₅₀=135 nM), and inhibits IL-17F production from stimulated human PBMCs with IC₅₀ of 2-4 nM.

IMU-935 demonstrates a strong inhibition of GM-CSF, IL-17A, IL-17F and IL-22 in inflamed human skin model (skin punches from human healthy volunteers).

IMU-935 inhibits Th17 differentiation and reduced EAE severity without affecting thymocyte development by selectively targeting the ROR γ t-CBF β interaction in Th17 cells but not in thymocytes.

References

Patent WO2019048541. 2019-03-14.

2. Wu H, et al. *J Clin Invest*. 2026 Jan 2;136(1):e185942.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com
